Sign in
CompletedNo phase

Preoperative Prophylactic Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Postpercutaneous Nephrolithotomy Infectious Complications and Sepsis.

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
210 people enrolled
Started
1 Jan 2023
Ended
1 Jan 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PCNL
Record updated
21 January 2026

Who can take part

Age
15 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • adult patients with renal stones scheduled for PCNL

Who cannot take part

  • Unfit patients for surgery
  • patients with active UT
  • uncorrected coagulopathy
  • pregnancy
  • children

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized controlled trial comparing the use of preoperative prophylactic single dose fosfomycin trometamol versus levofloxacin in prevention of post-PCNL infectious complications and sepsis.

Read full original descriptionShow less

the 3 groups were compared as regards the baseline data, preoperative data, intra-operative data, and post-op data.

The 3 groups in the trial

  • Preoperative Fosfomycin Trometamol groupExisting treatment, for comparison

    Fosfomycin before PCNL

    Treatment: PCNL

  • Preoperative 5-day Levofloxacin groupExisting treatment, for comparison

    Levofloxacin before PCNL

    Treatment: PCNL

  • No preopertive antibiotic groupOther group

    control, no preoperative antibiotic before PCNL

    Treatment: PCNL

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Preoperative Prophylactic Single Dose Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Post-percutaneous Nephrolithotomy Infectious Complications and Sepsis: A Prospective Randomized Controlled Trial.
Record updated
21 January 2026